Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 220

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 220
---
 financial, currency exchange, securities or commodity market conditions in 
 Canada or the United States or elsewhere;                                                                   |

| (D) | changes to the global, national or regional political conditions, including the outbreak of war or acts of 
 terrorism;                                                                                                 |

| (E) | any hurricane, flood, tornado, earthquake or other natural disaster, epidemic, pandemic or disease outbreak, or 
 any material worsening of such conditions existing as of the date of this Agreement;                            |

| (F) | relating to a change in the market trading price or trading volume of the Company’s publicly listed                                                                                                                      
 securities (it being understood that, unless otherwise excluded by (A) through (K) inclusively, the causes underlying any such change may be considered to determine whether same constitute a Material Adverse Change); |

| (G) | the failure of the Company to meet any internal or published projections, forecasts or estimates of revenues,                                                                                                                                
 earnings or cash flow (it being understood that, unless otherwise excluded by Sections (A) through (K) inclusively, the causes underlying any such change may be considered to determine whether same constitute a Material Adverse Change); |

| (H) | the announcement of this Agreement and the transactions contemplated hereby, including the Contemplated                                                                                                                                  
 Transactions and the Distribution (provided that this clause (H) shall not apply to any representation or warranty (or any Party’s obligation to consummate the Agreement relating to such representation or warranty) to the extent the 
 purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Agreement and the other transactions contemplated hereby);              |

| (I) | any matter expressly consented to in writing by the Purchaser after the date hereof or any action or inaction 
 expressly required by this Agreement; or                                                                      |

| (J) | any Permitted Disposition; |

| provided, however, that where the change or effect referred to in (A) through (E) primarily relates only                                                                                                                                                  
 to (or has the effect of primarily relating only to) the Company and its Subsidiary or disproportionately affects the Company and its Subsidiary, taken as a whole, compared to other entities of similar size operating in the same jurisdictions in the 
 industries and businesses in which the Company and its Subsidiary operate, such change or effect may be taken into account in determining whether a Material Adverse Change has occurred, but only to the extent of such disproportionate impact;